Edge Therapeutics Company Profile (NASDAQ:EDGE)

About Edge Therapeutics

Edge Therapeutics logoEdge Therapeutics, Inc. is a clinical-stage biotechnology company. The Company discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening conditions. The Company's product candidates include EG-1962 and EG-1964. The Company's lead product candidate, EG-1962, is initially being developed to improve clinical outcomes following subarachnoid hemorrhage (SAH) by administration through an external ventricular drain (EVD). Its second product candidate, EG-1964, contains aprotinin, a pancreatic trypsin inhibitor initially marketed as Trasylol, and is being developed using its Precisa development platform for the management of chronic subdural hematoma (cSDH), as a prophylactic treatment to prevent recurrent bleeding. Its product candidates utilize its Precisa development platform, which allows the Company to create therapeutics that are based on specific physical and chemical properties.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EDGE
  • CUSIP:
Key Metrics:
  • Previous Close: $8.97
  • 50 Day Moving Average: $9.55
  • 200 Day Moving Average: $8.74
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.58
  • P/E Growth: -0.07
  • Market Cap: $259.50M
  • Outstanding Shares: 28,898,000
Additional Links:
Companies Related to Edge Therapeutics:

Analyst Ratings

Consensus Ratings for Edge Therapeutics (NASDAQ:EDGE) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $22.50 (152.24% upside)

Analysts' Ratings History for Edge Therapeutics (NASDAQ:EDGE)
Show:
DateFirmActionRatingPrice TargetDetails
5/9/2016Credit Suisse Group AGLower Price TargetOutperform$19.00 -> $18.00View Rating Details
3/11/2016Leerink SwannReiterated RatingOutperform$27.00 -> $24.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$34.00 -> $18.00View Rating Details
10/26/2015GuggenheimInitiated CoverageBuy$30.00View Rating Details
(Data available from 8/29/2014 forward)

Earnings

Earnings History for Edge Therapeutics (NASDAQ:EDGE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/4/2016        
8/3/2016Q2($0.38)($0.33)ViewListenView Earnings Details
5/3/2016($0.34)($0.32)ViewListenView Earnings Details
3/8/2016Q4($0.32)($0.30)ViewListenView Earnings Details
11/6/2015Q315($0.23)($7.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Edge Therapeutics (NASDAQ:EDGE)
Current Year EPS Consensus Estimate: $-1.47 EPS
Next Year EPS Consensus Estimate: $-1.60 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.42)($0.42)($0.42)
Q2 20161($0.43)($0.43)($0.43)
Q3 20161($0.38)($0.38)($0.38)
Q4 20161($0.41)($0.41)($0.41)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Edge Therapeutics (NASDAQ:EDGE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Edge Therapeutics (NASDAQ:EDGE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/8/2016W Bradford MiddlekauffVPBuy10,000$9.48$94,800.00View SEC Filing  
8/1/2016Brian A LeuthnerInsiderSell7,500$9.54$71,550.00View SEC Filing  
3/11/2016James HealyDirectorBuy541,343$7.30$3,951,803.90View SEC Filing  
10/6/2015Andrew J. EinhornCFOBuy45,000$11.00$495,000.00View SEC Filing  
10/6/2015James HealyDirectorBuy450,000$11.00$4,950,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Edge Therapeutics (NASDAQ:EDGE)
DateHeadline
News IconBiotech one step closer to bowel disease treatment (NASDAQ:EDGE)
scienceblog.com - August 22 at 4:49 PM
News IconThe Green Rush: Searching for (High) Yields (NASDAQ:EDGE)
wire.kapitall.com - August 22 at 4:49 PM
globenewswire.com logoEdge Therapeutics, Inc. (Nasdaq: EDGE) to Ring The Nasdaq Stock ... - GlobeNewswire (press release) (NASDAQ:EDGE)
globenewswire.com - August 20 at 8:12 AM
einnews.com logoEdge Therapeutics, Inc. (Nasdaq: EDGE) to Ring The Nasdaq Stock Market Closing Bell - EIN News (press release) (NASDAQ:EDGE)
www.einnews.com - August 19 at 3:52 PM
publicnow.com logoEdge Therapeutics, Inc. (Nasdaq: EDGE) to Ring The Nasdaq Stock Market Closing Bell (NASDAQ:EDGE)
www.publicnow.com - August 19 at 3:52 PM
News IconDigital therapeutics market worth 457.9 million USD by 2021 according to new research report (NASDAQ:EDGE)
www.whatech.com - August 19 at 7:44 AM
News IconShares Moving Lower Over the Past Month Edge Therapeutics, Inc. (:EDGE) - Post News (NASDAQ:EDGE)
www.kentuckypostnews.com - August 18 at 7:26 AM
finance.yahoo.com logoEDGE THERAPEUTICS, INC. Financials (NASDAQ:EDGE)
finance.yahoo.com - August 11 at 4:55 PM
fidaily.com logoEdge Therapeutics, Inc. (NASDAQ:EDGE) Trading Unchanged - Insider Trading Activity - Finance Daily (NASDAQ:EDGE)
www.fidaily.com - August 9 at 8:59 PM
twst.com logoEdge Therapeutics Inc.: Edge Therapeutics Reports Second Quarter Financial Results and Recent Highlights (NASDAQ:EDGE)
www.twst.com - August 4 at 4:58 PM
finance.yahoo.com logoEdited Transcript of EDGE earnings conference call or presentation 3-Aug-16 12:30pm GMT (NASDAQ:EDGE)
finance.yahoo.com - August 4 at 7:53 AM
reuters.com logoBRIEF-Edge Therapeutics reports Q2 loss per share $0.33 - Reuters (NASDAQ:EDGE)
www.reuters.com - August 3 at 10:24 PM
seekingalpha.com logoEdge Therapeutics' (EDGE) CEO Brian Leuthner on Q2 2016 ... - Seeking Alpha (NASDAQ:EDGE)
seekingalpha.com - August 3 at 10:24 PM
biz.yahoo.com logoEdge Therapeutics Inc Earnings Call (Q2 2016) (NASDAQ:EDGE)
biz.yahoo.com - August 3 at 4:54 PM
seekingalpha.com logoEdge Therapeutics' (EDGE) CEO Brian Leuthner on Q2 2016 Results - Earnings Call Transcript (NASDAQ:EDGE)
seekingalpha.com - August 3 at 4:54 PM
finance.yahoo.com logoEdge Therapeutics Reports Second Quarter Financial Results and Recent Highlights (NASDAQ:EDGE)
finance.yahoo.com - August 3 at 4:54 PM
biz.yahoo.com logoEDGE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E (NASDAQ:EDGE)
biz.yahoo.com - August 3 at 4:54 PM
globenewswire.com logoEdge Therapeutics Reports Second Quarter Financial Results and Recent Highlights - GlobeNewswire (press release) (NASDAQ:EDGE)
globenewswire.com - August 3 at 7:35 AM
sg.finance.yahoo.com logoEdge Therapeutics reports 2Q loss (NASDAQ:EDGE)
sg.finance.yahoo.com - August 3 at 7:35 AM
biz.yahoo.com logoQ2 2016 Edge Therapeutics Inc Earnings Release - Before Market Open (NASDAQ:EDGE)
biz.yahoo.com - August 3 at 7:35 AM
biz.yahoo.com logoEdge Therapeutics Inc Earnings Call scheduled for 8:30 am ET today (NASDAQ:EDGE)
biz.yahoo.com - August 3 at 7:35 AM
biz.yahoo.com logoEDGE THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financia (NASDAQ:EDGE)
biz.yahoo.com - August 2 at 4:55 PM
reuters.com logoBRIEF-Edge Therapeutics says closing a dual-tranche term loan with Hercules Capital - Reuters (NASDAQ:EDGE)
www.reuters.com - August 2 at 9:34 AM
globenewswire.com logoEdge Therapeutics Announces Closing of $20 Million Debt Facility ... - GlobeNewswire (press release) (NASDAQ:EDGE)
globenewswire.com - August 2 at 9:34 AM
finance.yahoo.com logo6:36 am Edge Therapeutics closes a $20 million dual-tranche term loan (NASDAQ:EDGE)
finance.yahoo.com - August 2 at 9:34 AM
publicnow.com logoEdge Therapeutics Announces Closing of $20 Million Debt Facility with Hercules Capital, Inc. (NASDAQ:EDGE)
www.publicnow.com - August 2 at 9:34 AM
biz.yahoo.com logoEDGE THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:EDGE)
biz.yahoo.com - August 1 at 8:33 AM
streetinsider.com logoEdge Therapeutics (EDGE) Commences Treatment of First NEWTON 2 Patient (NASDAQ:EDGE)
www.streetinsider.com - July 30 at 4:25 PM
4-traders.com logoEdge Therapeutics : Announces First Patient Treated in Phase 3 NEWTON 2 Study of EG-1962 in Adult Patients with Aneurysmal Subarachnoid Hemorrhage (NASDAQ:EDGE)
www.4-traders.com - July 30 at 4:25 PM
streetinsider.com logoEdge Therapeutics (EDGE) Commences Treatment of First NEWTON 2 Patient - StreetInsider.com (NASDAQ:EDGE)
www.streetinsider.com - July 29 at 10:06 PM
publicnow.com logoEdge Therapeutics Announces First Patient Treated in Phase 3 NEWTON 2 Study of EG-1962 in Adult Patients with Aneurysmal Subarachnoid Hemorrhage (NASDAQ:EDGE)
www.publicnow.com - July 29 at 6:48 AM
publicnow.com logoEdge Therapeutics to Host Conference Call on August 3, 2016 to Discuss Second Quarter Financial Results (NASDAQ:EDGE)
www.publicnow.com - July 27 at 7:58 AM
prnewswire.com logoFDA Lifts Clinical Hold On CGF166 (NASDAQ:EDGE)
www.prnewswire.com - July 25 at 9:28 AM
News IconEdge Therapeutics Incorporated (NASDAQ:EDGE) Shorted Shares Increased 44.4% After Market Selling - Consumer Eagle (NASDAQ:EDGE)
www.consumereagle.com - July 20 at 5:58 PM
fiscalstandard.com logoNext Weeks Broker Price Targets For Edge Therapeutics, Inc. (NASDAQ:EDGE) - Fiscal Standard (NASDAQ:EDGE)
www.fiscalstandard.com - July 17 at 4:28 PM
News IconEdge Therapeutics Incorporated (NASDAQ:EDGE) Sellers Covered 5.26% of Their Shorts - Consumer Eagle (NASDAQ:EDGE)
www.consumereagle.com - July 15 at 11:47 AM
News IconHow Analysts Rated Edge Therapeutics Inc (NASDAQ:EDGE) Last Week? - Consumer Eagle (NASDAQ:EDGE)
www.consumereagle.com - July 15 at 11:47 AM
News Icon$17M supports five genomic application projects (NASDAQ:EDGE)
www.labcanada.com - July 13 at 10:00 PM
News IconShares Losing Ground for the Month; Investor Alert on Edge Therapeutics, Inc. (:EDGE) - Engelwood Daily (NASDAQ:EDGE)
www.engelwooddaily.com - July 13 at 8:29 AM
fiscalstandard.com logoBroker Outlook For Edge Therapeutics, Inc. (NASDAQ:EDGE) - Fiscal Standard (NASDAQ:EDGE)
www.fiscalstandard.com - July 13 at 8:29 AM
finance.yahoo.com logoNew genomic application projects to spur innovation across many Canadian sectors (NASDAQ:EDGE)
finance.yahoo.com - July 11 at 4:46 PM
News IconStock on the Rise for the Quarter: Edge Therapeutics, Inc. (:EDGE) - Engelwood Daily (NASDAQ:EDGE)
www.engelwooddaily.com - July 11 at 9:33 AM
News IconEdge Therapeutics Incorporated (NASDAQ:EDGE) Shorts Decreased by 5.26% After Short Covering - Press Telegraph (NASDAQ:EDGE)
presstelegraph.com - July 10 at 9:17 AM
ftsenews.co.uk logoNew Broker Ratings For Edge Therapeutics, Inc. (NASDAQ:EDGE) - FTSE News (NASDAQ:EDGE)
www.ftsenews.co.uk - July 9 at 8:15 AM
News IconIncreased Volatility on Shares of: Edge Therapeutics, Inc. (:EDGE) - Engelwood Daily (NASDAQ:EDGE)
www.engelwooddaily.com - July 9 at 8:15 AM
thestreet.com logoStock Futures Edge Higher Ahead of June Jobs Report - TheStreet.com (NASDAQ:EDGE)
www.thestreet.com - July 8 at 8:39 AM
streetinsider.com logoAgile Therapeutics' (AGRX) Latest Hire Should Boost Key Ortho Evra Launch - Noble Financial - StreetInsider.com (NASDAQ:EDGE)
www.streetinsider.com - July 7 at 9:56 PM
nasdaq.com logoEuropean ADRs Edge Lower as Banking Losses Offset Pharma Gains - Nasdaq (NASDAQ:EDGE)
www.nasdaq.com - July 7 at 8:12 AM
News IconEdge Therapeutics Incorporated (NASDAQ:EDGE) Shorted Shares Decreased By 5.26% - Press Telegraph (NASDAQ:EDGE)
presstelegraph.com - July 7 at 8:12 AM
News IconIncreased Volatility Watch for: Edge Therapeutics, Inc. (:EDGE) - Engelwood Daily (NASDAQ:EDGE)
www.engelwooddaily.com - July 7 at 8:12 AM

Social

Edge Therapeutics (NASDAQ:EDGE) Chart for Monday, August, 29, 2016


Last Updated on 8/29/2016 by MarketBeat.com Staff